CBER/CDER Guidances Drug Encyclopedia FDA Center for Biologics Evaluation and Research FDA Center for Drug Evaluation and Research FDA Center for Devices and Radiological Health FDA Compliance/Inspection FDA Office of Regulatory Affairs FOI/FDA Warning Letters Patent Extensions Recent Warning Letters Title 21 Code of Federal Regulations US Drug Master Files US Veterinary Master Files

FDA Approval Activities for this Drug… Omnicef (cefdinir) Capsules, Abbott NDA 50-739/S-006 7/24/02 8/6/02 Omnicef (cefdinir) Capsules, Parke-Davis NDA 50-739/S-002 11/24/99 12/30/99 12/30/99 Omnicef (cefdinir) Powder Suspension Parke-Davis NDA 50-749/SE2-002 7/14/99 7/29/99 7/29/99 Omnicef Indication: 5-day dosing regimen (7 mg/kg BID) for the treatment of AOM Omnicef (cefdinir) for Oral Suspension, Abbott Laboratories, Control Supplement Omnicef (cefdinir) capsules, Abbott Laboratories, Labeling Revision | Omnicef (cefdinir) capsules, Abbott Laboratories, Labeling Revision | Omnicef (cefdinir) powder for oral suspension, Abbott Laboratories, Labeling Revision | Cefdinir Capsules, Lupin Ltd., Approval | Cefdinir Oral Suspension, Lupin Ltd., Approval | Cefdinir Capsules, Sandoz Inc., Approval | Cefdinir Oral Suspension, Sandoz Inc., Approval | Cefdinir Oral Suspension, Teva Pharma, Approval | Cefdinir Capsules, Teva Pharma, Approval | OMNICEF (cefdinir) Capsules, Abbott Labs, Labeling Revision | OMNICEF Oral Suspension, Abbott Labs, Labeling Revision | Cefdinir Capsules, Orchid Healthcare, Approval | Cefdinir Oral Suspension, Orchid Healthcare, Approval | OMNICEF (cefdinir) Capsules, Abbott Labs, Labeling Revision | OMNICEF (cefdinir) Oral Suspension, Abbott Labs, Labeling Revision For the latest approval list, check this API's main page.                                                                                      A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | DMF Index | Pharma Job Search | Pharma Company News © 2009 Betterchem.com